Myotonic Dystrophy Drug Market
Global Myotonic Dystrophy Drug Market Size, Share & Trends Analysis Report by Drug Type (Sodium Channel Blockers, NSAIDs, Antidepressants, and Others), by Route of Administration (Oral, Intravenous), and by Distribution Channel (Online Pharmacies, Offline Pharmacies) Forecast 2022-2028 Update Available - Forecast 2024-2030
The global myotonic dystrophy drug market is anticipated to grow at a significant CAGR of 7.6% during the forecast period. Myotonic dystrophy is the most common form of muscular dystrophy in adults and is characterized by myopathy, myotonia, and multiorgan involvement. It is a gradual and progressive disorder that affects skeletal muscles, uterine muscle, heart, and central nervous system. The global myotonic dystrophy market is growing due to various government initiatives focusing on increasing investment in the pharmaceutical and drug sector for efficiency and comfort of drug delivery as well as the development of the healthcare sector globally. Additionally, the increasing patients of with weak muscles, joint dysfunction, respiratory failure, and many more diseases are some important factors that are boosting the growth of the market in the forecasted period. For instance, According to the National Library of Medicine, One in every 8,000 people in the world suffers from myotonic dystrophy.
Impact of COVID-19 Pandemic on Global Myotonic Dystrophy Drug Market
COVID-19 pandemic has affected the global myotonic dystrophy drug market in a negative way. According to the Myotonic Dystrophy Foundation, COVID-19 has a disproportionate impact with people and families affected with myotonic dystrophy. COVID-19 causes lungs and heart complications and considered as a significant cause of myotonic dystrophy. But, due to several regulations by government authorities like temporary lockdown and shutdowns of manufacturing units and working with less number of employees, the supply chain was disrupted. COVID-19 has resulted in the slowdown in the critical trade activities globally.
Segmental Outlook
The global myotonic dystrophy drug market is segmented based on the drug type, route of administration, and distribution channel. Based on the drug type, the market is segmented intoanti-myotonic drugs, NSAIDs, antidepressants, and others. Based on the route of administration, the market is sub-segmented into oral and intravenous. Based on the distribution channel, the market is sub-segmented into online pharmacies and offline pharmacies. Amongst the drug type segmentation, the anti-myotonic drugs segment is anticipated to hold the major share. Amongst the route of administration, the oral route of administration is estimated to grow more. Amongst the distribution channel, the offline pharmacy segment is estimated to grow more in the forecast period.
Global Myotonic Dystrophy Drug Market Share by Drug Type, 2022 (%)
The Antidepressants Segment is Anticipated to Hold a Prominent Share in the Global Myotonic Dystrophy Drug Market
Antidepressant drugs such as clomipramine or imipramine, benzodiazepines, calcium antagonists, taurine, and prednisone are also prescribed by doctors to treat myotonic dystrophy and are anticipated to hold the fastest-growing share in the forecasted period. According to the research by NCBI, sodium channel blockers reduce DMPK, mRNA proteins and gets associated with high-risk events. So, it is anticipated that, antidepressant drugs with hold the fastest-growing share in the global myotonic dystrophy drug market.
The Oral Route of Administration Segment is Anticipated to Show Notable Growth in the Global Myotonic Dystrophy Drug Market
Based on the route of application, the oral route of administration is anticipated to hold the major share in the global myotonic dystrophy drug market. Myotonic Dystrophy drugs are prescribed by professional doctors only after a proper diagnosis. Generally, doctors prescribe mexiletine sodium channel blockers to treat myotonic dystrophy in oral form. NCBI approved that mexiletine is an effective treatment to treat myotonic dystrophy in oral form. The oral route of administration is anticipated to hold the major share in the global myotonic dystrophy market.
The Offline Pharmacy Distribution Channel is Anticipated to hold the Major Share in the Global Myotonic Dystrophy Drug Market
Based on the distribution channel, the offline pharmacy is anticipated to hold the major share in the global myotonic dystrophy drug market. This is a kind of drug that is only prescribed by professional medical practitioners after proper diagnosis. It is estimated that the customers are more likely to buy from offline pharmacies like hospital pharmacies or retail medical shops after getting a prescription from the doctor. So, the offline pharmacy distribution channel is anticipated to hold the major share in the global myotonic dystrophy drug market. Online pharmacies can have the fastest-growing share due to the increased demand for online pharmacies for their all-time availability of medicines, huge discounts, and due to ease and convenience.
Regional Outlooks
The global myotonic dystrophy drug market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The North American region myotonic dystrophy drug market is expected to hold prominent market share due to the high prevalence of disease in this region. Asia-Pacific region is predicted to be the fastest growing in the global myotonic dystrophy drug market. Various government initiatives aimed at increasing investments towards the pharmaceutical and healthcare sector is the key factor enhancing the market growth. Moreover, prevalence of muscle weakness, temporomandibular joint dysfunction, diabetes, and other diseases among geriatric population is creating wide scope for the myotonic dystrophy drug market.
Global Myotonic Dystrophy Drug Market Growth, by Region 2022-2028
The North America Region is estimated to hold the Major Share in the Global Myotonic Dystrophy Drug Market
The North American region is anticipated to hold a prominent share in the global myotonic dystrophy drug market. This is due to the high prevalence of disease such as respiratory failure , muscle weakness , joint dysfunction and other in this region. The National Institute of Health is constantly focusing on research activities related to myotonic dystrophy to develop a new level of drugs to treat the patients. The increasing number of R&D activities in this region along with the clinical trials is boosting the North American myotonic dystrophy drug market growth.
Market Players Outlook
The major companies serving the global myotonic dystrophy drug market include ANI Pharmaceuticals, Inc., Lupin Ltd., Mylan N.V., Novartis AG, Teva Pharmaceutical Industries Ltd., and many more. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in July 2021, orally administrated tideglusib, developed by AMO PHARMA cleared their phase 2 trials on patients with myotonic dystrophy.
The Report Covers
- Market value data analysis of 2022 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global myotonic dystrophy drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on The Global Myotonic Dystrophy Drug Market
• Recovery Scenario of Global Myotonic Dystrophy Drug Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Sanofi, S.A.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Lupin Ltd.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Pfizer Inc.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Novartis AG
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Teva Pharmaceutical Industries Ltd.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Myotonic Dystrophy Drug Market by Drug Type
4.1.1. Anti-Myotonic Drugs
4.1.2. Nonsterodial Anti-Inflammatories (NSAIDs)
4.1.3. Antidepressants
4.1.4. Others
4.2. Global Myotonic Dystrophy Drug Market by Route of Administration
4.2.1. Oral
4.2.2. Intravenous
4.3. Global Myotonic Dystrophy Drug Market by Distribution channel
4.3.1. Offline Pharmacies
4.3.2. Online Pharmacies
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. ANI Pharmaceuticals Inc.
6.2. BioMarin Pharmaceutical IncBioMarin
6.3. Boehringer Ingelheim International GmbH
6.4. Bristol-Myers Squibb Co.
6.5. C.H. Boehringer Sohn AG & Ko. KG
6.6. ECHEMI Technology Co. Ltd.
6.7. F. Hoffman- La Roche Ltd.
6.8. Ionic Pharmaceuticals, Inc.
6.9. Lannett Co, Inc
6.10. Mallinckrodt PharmaceuticalsMallinckrodt
6.11. Marina Biotech Inc.
6.12. Pfizer Inc.
6.13. Pharma Circle LLC
6.14. Sanofi Apotex Pharmaceutical Holdings Inc.
6.15. Sun Pharmaceuticals Industries Ltd.
1. GLOBAL MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022 - 2028 ($ MILLION)
2. GLOBAL ANTI-MYOTONIC DRUGSMARKET RESEARCH AND ANALYSIS BY REGION, 2022 - 2028 ($ MILLION)
3. GLOBAL NSAIDS MYOTONIC DYSTROPHY DRUG TYPE MARKET RESEARCH AND ANALYSIS BY REGION, 2022 - 2028 ($ MILLION)
4. GLOBAL ANTI DEPRESSANTS MYOTONIC DYSTROPHY DRUG TYPE MARKET RESEARCH AND ANALYSIS BY REGION, 2022 - 2028 ($ MILLION)
5. GLOBAL OTHERS MYOTONIC DYSTROPHY DRUG TYPE MARKET RESEARCH AND ANALYSIS BY REGION, 2022 - 2028 ($ MILLION)
6. GLOBAL MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2022 - 2028 ($ MILLION)
7. GLOBAL MYOTONIC DYSTROPHY DRUG BY ORAL MARKET RESEARCH AND ANALYSIS BY REGION, 2022 - 2028 ($ MILLION)
8. GLOBAL MYOTONIC DYSTROPHY DRUG BY INTRAVENOUS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 - 2028 ($ MILLION)
9. GLOBAL MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022 - 2028 ($ MILLION)
10. GLOBAL ONLINE MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2022 - 2028 ($ MILLION)
11. GLOBAL OFFLINE MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2022 - 2028 ($ MILLION)
12. GLOBAL MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2022 - 2028 ($ MILLION)
13. NORTH AMERICAN MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022 - 2028 ($ MILLION)
14. NORTH AMERICAN MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022 - 2028 ($ MILLION)
15. NORTH AMERICAN MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2022 - 2028 ($ MILLION)
16. NORTH AMERICAN MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022 - 2028 ($ MILLION)
17. EUROPEAN MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022 - 2028 ($ MILLION)
18. EUROPEAN MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022 - 2028 ($ MILLION)
19. EUROPEAN MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2022 - 2028 ($ MILLION)
20. EUROPEAN MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022 - 2028 ($ MILLION)
21. ASIA-PACIFIC MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022 - 2028 ($ MILLION)
22. ASIA-PACIFIC MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022 - 2028 ($ MILLION)
23. ASIA-PACIFIC MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2022 - 2028 ($ MILLION)
24. ASIA-PACIFIC MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022 - 2028 ($ MILLION)
25. REST OF THE WORLD MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022 - 2028 ($ MILLION)
26. REST OF THE WORLD MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022 - 2028 ($ MILLION)
27. REST OF THE WORLD MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2022 - 2028 ($ MILLION)
28. REST OF THE WORLD MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022 - 2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL MYOTONIC DYSTROPHY DRUG MARKET, 2022 - 2028($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL MYOTONIC DYSTROPHY DRUG MARKET BY SEGMENT, 2022 - 2028($ MILLION)
3. GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SHARE BY DRUG TYPE, 2022 VS 2028 (%)
4. RECOVERY OF GLOBAL MYOTONIC DYSTROPHY DRUG MARKET, 2022-2028 (%)
5. GLOBAL ANTI-MYOTONIC DRUGSMARKET SHARE BY GEOGRAPHY, 2022 VS 2028 (%)
6. GLOBAL NSAIDS MYOTONIC DYSTROPHY DRUG MARKET SHARE BY GEOGRAPHY, 2022 VS 2028 (%)
7. GLOBAL ANTIDEPRESSANTS MYOTONIC DYSTROPHY DRUG MARKET SHARE BY GEOGRAPHY, 2022 VS 2028 (%)
8. GLOBAL OTHERS MYOTONIC DYSTROPHY DRUG MARKET SHARE BY GEOGRAPHY, 2022 VS 2028 (%)
9. GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SHARE BY ROUTE OF ADMINISTRATION, 2022 VS 2028 (%)
10. GLOBAL MYOTONIC DYSTROPHY DRUG BY ORAL MARKET SHARE BY GEOGRAPHY, 2022 VS 2028 (%)
11. GLOBAL MYOTONIC DYSTROPHY DRUG BY INTRAVENOUS MARKET SHARE BY GEOGRAPHY, 2022 VS 2028 (%)
12. GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SHARE BY DISTRIBUTION CHANNEL, 2022 VS 2028 (%)
13. GLOBAL ONLINE MYOTONIC DYSTROPHY DRUG MARKET SHARE BY GEOGRAPHY, 2022 VS 2028 (%)
14. GLOBAL OFFLINE MYOTONIC DYSTROPHY DRUG MARKET SHARE BY GEOGRAPHY, 2022 VS 2028 (%)
15. GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SHARE BY GEOGRAPHY, 2022 VS 2028 (%)
16. US GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
17. CANADA GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
18. UK GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
19. FRANCE GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
20. GERMANY GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
21. ITALY GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
22. SPAIN GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
23. REST OF EUROPE GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
24. INDIA GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
25. CHINA GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
26. JAPAN GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
27. REST OF ASIA-PACIFIC GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
28. REST OF THE WORLD GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
